ReNeuron Group plc Share Purchase by Senior Independent NED (0589D)

TIDMRENE

RNS Number : 0589D

ReNeuron Group plc

16 June 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

Share Purchase by Senior Independent Non-executive Director

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that Barbara Staehelin, Senior Independent Non-executive Director of the Company, has today purchased 150,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").

 
 Name                 Title                              Number of          Resulting      Percentage 
                                                          Ordinary         beneficial    of Company's 
                                                  Shares purchased        interest in    Total Voting 
                                                                        the Company's          Rights 
                                                                      Ordinary Shares 
                      Senior Independent 
 Barbara Staehelin     Non-Executive Director              150,000            500,000           0.88% 
                     -------------------------  ------------------  -----------------  -------------- 
 

ENDS

Enquiries:

 
 ReNeuron                                                                www.reneuron.com/investors 
 Iain Ross, Executive Chairman                                                      Via Walbrook PR 
 John Hawkins, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated 
  Adviser and Broker)                                                           [phone] 
 James Reeve/George Payne/Dan Dearden-Williams 
  (Corporate Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)            [phone] or [e-mail] 
 Paul McManus / Alice Woodings                                [phone] / [phone] 
                                                                                                654 
 
 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX(TM) platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                         Barbara Staehelin 
      ---------------------------  ------------------------------------------------ 
 2     Reason for the notification 
      ----------------------------------------------------------------------------- 
 a)    Position/status              Senior Independent Non-Executive Director 
      ---------------------------  ------------------------------------------------ 
 b)    Initial notification         Initial notification 
        /Amendment 
      ---------------------------  ------------------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------- 
 a)    Name                         ReNeuron Group plc 
      ---------------------------  ------------------------------------------------ 
 b)    LEI                          2138003TU12CQ5TZO137 
      ---------------------------  ------------------------------------------------ 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      ----------------------------------------------------------------------------- 
 a)    Description of               Ordinary Shares 1 pence 
        the financial instrument,    RENE - GB00BF5G6K95 
        type of instrument 
        Identification 
        code 
      ---------------------------  ------------------------------------------------ 
 b)    Nature of the transaction    Acquisition of ordinary shares 
      ---------------------------  ------------------------------------------------ 
 c)    Price(s) and volume(s)         Price(s) (pence)   Volume(s) 
                                       8.15p              150,000 
                                                         ---------- 
      ---------------------------  ------------------------------------------------ 
 d)    Aggregated information       150,000 ordinary shares at an average price 
                                     of GBP 0.0815 at a total value of GBP12,225.00 
      ---------------------------  ------------------------------------------------ 
 e)    Date of the transaction      16 June 2023 
      ---------------------------  ------------------------------------------------ 
 f)    Place of the transaction     London Stock Exchange AIM Market 
      ---------------------------  ------------------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPURUQUPWGQQ

(END) Dow Jones Newswires

June 16, 2023 12:12 ET (16:12 GMT)